Skip to content

Bioprotocols – Free online protocols for Biomedical Research

DNA extraction protocol, MSDS, Material Safety Data Sheet

Menu
  • Home
  • Epigenetics: The Final Frontier
  • Real-Time Observation of Carbonic Acid Formation
  • Two White Dwarfs with Oxygen-Rich
  • Distributors
  • Contact us
Menu

Life Technologies

Posted on April 13, 2021April 13, 2021 by Oscar

The fact is that siRNAs—the double-stranded effectors of RNA interference (RNAi)—can “be developed to silence any gene; can be developed incredibly fast; can have picomolar efficacy; [and] can have an effect that lasts for weeks.”

  • In the lab, they have become invaluable tools,
  • enabling the easy genetic knockdown of any sequence.
  • The problem with migrating to the clinic, she says, is still delivery.
Laboratory technician looking through microscope when her colleague working on computer and filling research documents

Two years is a long time in the world of RNAi therapeutics. Since Science last covered the topic in 2007, the first Phase 3 human clinical trial of an siRNA drug has been prematurely terminated; new off-target effects have been identified; and the first miRNA-based therapeutic entered clinical trials. Yet much remains the same, especially the biggest challenge: delivery. As researchers struggle to overcome these obstacles, optimism persists undiminished.

Work on that front is proceeding at a rapid clip, in both academia and industry, as a handful of clinical trials attest. At the same time, new problems have cropped up, including unanticipated immunological effects and impacts on endogenous RNA processing. Others are probing the potential of the field as a whole, for instance with so-called “single-stranded” RNAi strategies.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Investigating Glycosylation Patterns with Mass Spectrometric Analysis: A transformative development in Bioconjugation and Pharmaceutical Development
  • Navigating Glycan-Protein Interaction Repositories: Advancing Therapeutic Discovery and Breakthroughs
  • Exploring Carbohydrate-Protein Interaction Platforms: Advancing Therapeutic Discovery and Innovation
  • Glycan-Based Treatments: Exploring the Potential of Glycan Research in Advanced Medical Treatment
  • Advancements in Glycan Biosynthesis: Transforming the Advancement of Biotechnological Production and Therapeutics

Recent Comments

    Categories

    • antibody
    • Blog
    • cDNA
    • dna
    • elisa kits
    • pcr
    • peptide
    • rna
    • Uncategorized
    • vector
    July 2025
    M T W T F S S
     123456
    78910111213
    14151617181920
    21222324252627
    28293031  
    « Jun    

    Categories

    • antibody
    • Blog
    • cDNA
    • dna
    • elisa kits
    • pcr
    • peptide
    • rna
    • Uncategorized
    • vector

    Recent Posts

    • Investigating Glycosylation Patterns with Mass Spectrometric Analysis: A transformative development in Bioconjugation and Pharmaceutical Development
    • Navigating Glycan-Protein Interaction Repositories: Advancing Therapeutic Discovery and Breakthroughs
    • Exploring Carbohydrate-Protein Interaction Platforms: Advancing Therapeutic Discovery and Innovation
    • Glycan-Based Treatments: Exploring the Potential of Glycan Research in Advanced Medical Treatment
    • Advancements in Glycan Biosynthesis: Transforming the Advancement of Biotechnological Production and Therapeutics
    © 2025 Bioprotocols – Free online protocols for Biomedical Research | Powered by Superbs Personal Blog theme